JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.

@article{lvarezLarrn2014JAK2V617FMI,
  title={JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.},
  author={Alberto {\'A}lvarez-Larr{\'a}n and Beatriz Bellosillo and Arturo Pereira and Ana Kerguelen and Juan-Carlos Hern{\'a}ndez-Boluda and Luz Maria Martinez-Aviles and Concepci{\'o}n Fern{\'a}ndez-Rodr{\'i}guez and M A Carreiras G{\'o}mez and Luis J. Lombard{\'i}a and Anna Angona and {\'A}gueda Ancochea and Alicia Sen{\'i}n and Raquel Longar{\'o}n and Blanca Navarro and Mar{\'i}a Pilar Collado and Carlos Besses},
  journal={American journal of hematology},
  year={2014},
  volume={89 5},
  pages={517-23}
}
The JAK2V617F allele burden has been identified as a risk factor for vascular events and myelofibrotic transformation in polycythemia vera (PV) and essential thrombocythemia (ET). However, all previous studies have evaluated a single time point JAK2V617F measurement. Therefore, the frequency and the clinical significance of changes in the JAK2V617F mutant load occurring during the disease evolution remain unknown. In the present study, JAK2V617F monitoring was performed during the follow-up of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Similar Papers

Loading similar papers…